__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
About the molecule and how it works.
A specifically engineered anti-VEGF
A single-chain antibody fragment aims to facilitate deeper penetration of active molecules than larger molecules within tissue.1
The molecule
Beovu has a high affinity to VEGF-A isoforms1 and can inhibit VEGF through prevention of the ligand-receptor interaction.
VEGF, vascular endothelial growth factor; VEGF-A, vascular endothelial growth factor A.
References
- Gaudreault J et al. Invest Ophthalmol Vis Sci. 2012; 53: 3025.
- Novartis Pharmaceuticals UK Ltd. Beovu® (brolucizumab) Summary of Product Characteristics, Great Britain, April 2022.
- Novartis Pharmaceuticals UK Ltd. Beovu® (brolucizumab) Summary of Product Characteristics, Northern Ireland, March 2022.
- Yannuzzi NA, Freund KB. Clin Ophthalmol. 2019; 13: 1323–1329.
Rate this content:
UK | May 2022 | 207568
